摘要
目的 本研究针对冠心病患者使用阿托伐他汀、曲美他嗪联合治疗,并对疗效做出分析。方法 60例冠心病患者,通过随机抽样法分为常规组、研究组,各30例。常规组采用曲美他嗪治疗,研究组采用阿托伐他汀+曲美他嗪治疗。比较两组患者的疗效、血脂指标、内皮功能指标、心功能指标、心绞痛发作情况。结果 研究组总有效率为90.00%,高于常规组的66.67%,差异性具有统计学价值(P<0.05)。治疗后,研究组总胆固醇(3.73±0.05)mmol/L、甘油三酯(1.05±0.14)mmol/L、低密度脂蛋白胆固醇(1.16±0.20)mmol/L低于常规组的(5.18±0.66)、(1.88±0.36)、(3.37±0.95)mmol/L,高密度脂蛋白胆固醇(1.88±0.36)mmol/L高于常规组的(1.04±0.11)mmol/L,差异性具有统计学价值(P<0.05)。治疗后,研究组一氧化氮(396.87±67.86)μg/L高于常规组的(310.13±50.88)μg/L,内皮素-1(50.05±2.02)μg/L、外周血循环内皮微颗粒(854.67±261.37)×10^(6)/L低于常规组的(87.76±4.28)μg/L、(1073.18±212.54)×10^(6)/L,差异性具有统计学价值(P<0.05)。治疗后,研究组左心室射血分数(52.28±2.84)%高于常规组的(40.80±2.56)%,左心室收缩末期内径(38.03±2.05)mm、左心室舒张末期内径(50.05±2.42)mm小于常规组的(58.78±3.36)、(66.68±4.18)mm,差异性具有统计学价值(P<0.05)。治疗后,研究组心绞痛持续时间(3.84±0.74)min/次短于常规组的(7.21±1.91)min/次、发作次数(2.72±0.44)次/周少于常规组的(4.73±0.74)次/周、疼痛程度评分(2.34±0.24)分低于常规组的(4.17±0.51)分,差异性具有统计学价值(P<0.05)。结论 冠心病患者使用阿托伐他汀+曲美他嗪联合治疗后,其心功能明显好转,心绞痛发作次数明显减少,可减轻患者疼痛程度,疗效显著,临床应用价值较高。
Objective To analyze the efficacy of atorvastatin combined with trimetazidine in the treatment of patients with coronary heart disease.Methods 60 patients with coronary heart disease were divided into a conventional group and a study group by random sampling method,each with 30 cases.The conventional group was treated with trimetazidine,and the study group was treated with atorvastatin+trimetazidine.The therapeutic effect,blood lipid index,endothelial function index,cardiac function index and attack of angina pectoris were compared between the two groups.Results The total effective rate of the study group was 90.00%,which was higher than 66.67%of the conventional group,and the difference was statistically significant(P<0.05).After treatment,the study group had total cholesterol of(3.73±0.05)mmol/L,triglyceride of(1.05±0.14)mmol/L and low density lipoprotein cholesterol of(1.16±0.20)mmol/L,which were lower than(5.18±0.66),(1.88±0.36)and(3.37±0.95)mmol/L in the conventional group;the high density lipoprotein cholesterol of(1.88±0.36)mmol/L in the study group was higher than(1.04±0.11)mmol/L in the conventional group;the difference was statistically significant(P<0.05).After treatment,the nitric oxide of(396.87±67.86)μg/L in the study group was higher than(310.13±50.88)μg/L in the conventional group;the study group had endothelin-1 of(50.05±2.02)μg/L and peripheral circulating endothelial microparticle of(854.67±261.37)×10^(6)/L,which were lower than(87.76±4.28)μg/L and(1073.18±212.54)×10^(6)/L in the conventional group;the difference was statistically significant(P<0.05).After treatment,the left ventricular ejection fraction of(52.28±2.84)%in the study group was higher than(40.80±2.56)%in the conventional group;the study group had left ventricular end-systolic diameter of(38.03±2.05)mm and left ventricular end-diastolic diameter of(50.05±2.42)mm,which were smaller than(58.78±3.36)and(66.68±4.18)mm in the conventional group;the difference was statistically significant(P<0.05).After treatmen
作者
孙立华
SUN Li-hua(Shenxian Yanta Street Community Health Service Center,Liaocheng 252400,China)
出处
《中国现代药物应用》
2024年第18期97-100,共4页
Chinese Journal of Modern Drug Application
关键词
阿托伐他汀
曲美他嗪
联合治疗
冠心病
Atorvastatin
Trimetazidine
Combination therapy
Coronary heart disease
